169.64
price up icon0.22%   0.38
after-market After Hours: 169.78 0.14 +0.08%
loading
Astrazeneca Plc stock is traded at $169.64, with a volume of 3.86M. It is up +0.22% in the last 24 hours and down -9.96% over the past month. A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$169.26
Open:
$170.08
24h Volume:
3.86M
Relative Volume:
1.72
Market Cap:
$263.09B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
50.95
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+3.11%
1M Performance:
-9.96%
6M Performance:
+77.45%
1Y Performance:
+133.47%
1-Day Range:
Value
$167.79
$173.24
1-Week Range:
Value
$164.81
$173.24
52-Week Range:
Value
$71.49
$212.71

Astrazeneca Plc Stock (AZN) Company Profile

Name
Name
Astrazeneca Plc
Name
Phone
-
Name
Address
-
Name
Employee
96,100
Name
Twitter
@AstraZeneca
Name
Next Earnings Date
2026-07-27
Name
Latest SEC Filings
Name
AZN's Discussions on Twitter

Compare AZN vs LLY, JNJ, ABBV, MRK, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
AZN icon
AZN
Astrazeneca Plc
169.64 262.50B 60.48B 10.40B 8.05B 3.3297
LLY icon
LLY
Lilly Eli Co
1,197.53 1.07T 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
265.95 634.77B 97.93B 21.04B 17.80B 8.6278
ABBV icon
ABBV
Abbvie Inc
256.91 458.24B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
130.76 323.72B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
156.11 294.63B 54.66B 13.58B 16.05B 7.0171

Astrazeneca Plc Stock (AZN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-27-26 Initiated Citigroup Buy
Oct-27-25 Resumed Jefferies Buy
Oct-16-25 Downgrade Deutsche Bank Hold → Sell
Apr-15-25 Initiated Exane BNP Paribas Outperform
Feb-13-25 Upgrade UBS Neutral → Buy
Feb-12-25 Initiated Morgan Stanley Overweight
Nov-20-24 Upgrade UBS Sell → Neutral
Nov-06-24 Upgrade Deutsche Bank Sell → Hold
Sep-13-24 Downgrade Deutsche Bank Hold → Sell
May-30-24 Initiated Goldman Buy
Apr-16-24 Upgrade Deutsche Bank Sell → Hold
Feb-08-24 Downgrade Deutsche Bank Hold → Sell
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Sell
Jan-03-24 Downgrade Jefferies Buy → Hold
Dec-18-23 Initiated HSBC Securities Buy
Sep-25-23 Upgrade Jefferies Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-12-23 Upgrade UBS Neutral → Buy
Jul-05-23 Downgrade Deutsche Bank Buy → Hold
Apr-11-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-05-23 Initiated BMO Capital Markets Outperform
Sep-15-22 Downgrade Credit Suisse Outperform → Neutral
Sep-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-29-22 Upgrade Argus Hold → Buy
Jun-14-22 Downgrade UBS Buy → Neutral
Feb-11-22 Upgrade DZ Bank Sell → Hold
Dec-07-21 Downgrade Jefferies Buy → Hold
Aug-12-21 Resumed JP Morgan Overweight
Apr-12-21 Downgrade Argus Buy → Hold
Mar-16-21 Upgrade Jefferies Hold → Buy
Feb-25-21 Upgrade UBS Neutral → Buy
Jan-15-21 Initiated Deutsche Bank Buy
Dec-07-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20 Upgrade UBS Sell → Neutral
Nov-11-20 Upgrade HSBC Securities Reduce → Hold
Sep-29-20 Initiated Berenberg Buy
Nov-22-19 Initiated SVB Leerink Outperform
Oct-25-19 Upgrade Liberum Hold → Buy
Apr-02-19 Downgrade UBS Neutral → Sell
Feb-05-19 Initiated Exane BNP Paribas Outperform
Jan-25-19 Upgrade Shore Capital Hold → Buy
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Aug-16-18 Downgrade Jefferies Buy → Hold
Mar-19-18 Upgrade Jefferies Hold → Buy
Feb-06-18 Reiterated Leerink Partners Mkt Perform
Feb-05-18 Reiterated Bernstein Outperform
Jan-18-18 Reiterated Leerink Partners Mkt Perform
Dec-29-17 Upgrade JP Morgan Neutral → Overweight
Oct-16-17 Upgrade Credit Suisse Neutral → Outperform
Sep-25-17 Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17 Upgrade Bernstein Mkt Perform → Outperform
View All

Astrazeneca Plc Stock (AZN) Latest News

pulisher
03:00 AM

AstraZeneca PLC (AZN) Q2 2026 Earnings Call Highlights: Strong Oncology and Rare Disease Growth ... - Yahoo Finance

03:00 AM
pulisher
01:54 AM

AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure - TradingView

01:54 AM
pulisher
12:40 PM

AstraZeneca’s MONTEROSA Study Tracks Real World Outcomes for STRIDE in Liver Cancer - TipRanks

12:40 PM
pulisher
12:33 PM

AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks (NYSE:AZN) - Seeking Alpha

12:33 PM
pulisher
12:14 PM

AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review

12:14 PM
pulisher
11:50 AM

AstraZeneca PLC (AZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

11:50 AM
pulisher
11:26 AM

AstraZeneca quarterly net profit rises 2% on strong cancer drug sales - Yahoo Finance UK

11:26 AM
pulisher
11:12 AM

AstraZeneca: In line Q2; correction of late is an entry point - marketscreener.com

11:12 AM
pulisher
10:21 AM

Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings - Benzinga

10:21 AM
pulisher
10:18 AM

AstraZeneca drug prices evolving in response to Trump policy, executive says - Reuters

10:18 AM
pulisher
10:09 AM

AstraZeneca PLC Stock Analysis: Q2 Earnings Beat vs Bearish Trend - The Cryptonomist

10:09 AM
pulisher
09:30 AM

Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

09:30 AM
pulisher
09:07 AM

AstraZeneca says adjusting drug pricing over Trump policies By Investing.com - Investing.com Nigeria

09:07 AM
pulisher
09:02 AM

Astrazeneca Q2 Earnings Call Highlights - Yahoo Finance

09:02 AM
pulisher
08:50 AM

What's Going on With AstraZeneca Stock Monday?AstraZeneca (NYSE:AZN) - Benzinga

08:50 AM
pulisher
07:52 AM

AstraZeneca (NASDAQ: AZN) lifts H1 profit and backs 2026 outlook - Stock Titan

07:52 AM
pulisher
07:32 AM

AstraZeneca oncology growth continues despite product setback - Investors' Chronicle

07:32 AM
pulisher
07:29 AM

AstraZeneca profit rises on strong cancer drug sales - Yahoo Finance UK

07:29 AM
pulisher
07:29 AM

AstraZeneca Sees 2030 Goal on Track as Cancer Drugs Drive Growth - WSJ

07:29 AM
pulisher
07:27 AM

ASTRAZENECA : Jefferies gives a Buy rating - marketscreener.com

07:27 AM
pulisher
07:08 AM

Mixed Ultomiris HSCT-TMA results at AstraZeneca (NASDAQ: AZN) spur paediatric filings - Stock Titan

07:08 AM
pulisher
07:00 AM

AstraZeneca to Acquire Worldwide Rights to Lung Cancer Drug for $600M - Stock Titan

07:00 AM
pulisher
06:58 AM

AstraZeneca sales boosted by soaring demand for cancer treatments - Yahoo Finance UK

06:58 AM
pulisher
06:57 AM

AstraZeneca (NASDAQ: AZN) Phase III Sone-Ve data show gastric survival gain - Stock Titan

06:57 AM
pulisher
06:45 AM

AstraZeneca PLC (AZN) Q2 FY2026 earnings call transcript - Yahoo Finance

06:45 AM
pulisher
06:22 AM

AstraZeneca stock edges up on earnings beat despite revenue miss - Investing.com

06:22 AM
pulisher
06:07 AM

AstraZeneca Q2 Core Earnings, Revenue Rise; Interim Dividend Raised - marketscreener.com

06:07 AM
pulisher
05:20 AM

AstraZeneca PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

05:20 AM
pulisher
05:20 AM

AstraZeneca reiterates guidance after topping Q2 profit expectations; shares up - Investing.com Nigeria

05:20 AM
pulisher
05:10 AM

Market Open: Vodafone raises guidance, AstraZeneca H1 growth - Yahoo Finance UK

05:10 AM
pulisher
05:07 AM

AstraZeneca CFO says AI is not expected to lead to job cuts - marketscreener.com

05:07 AM
pulisher
05:02 AM

AstraZeneca sales rise as demand for cancer treatments grow - Yahoo Finance UK

05:02 AM
pulisher
04:42 AM

AstraZeneca Logs Higher First-half Profit on Strong Oncology, Rare Disease Drugs Sales; Outlook Maintained - marketscreener.com

04:42 AM
pulisher
04:36 AM

AstraZeneca’s Cancer Medicines Spur Profit Growth - Bloomberg

04:36 AM
pulisher
04:19 AM

AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View - RTTNews

04:19 AM
pulisher
04:11 AM

AstraZeneca Q2 Results: Adjusted EPS rises 141% YoY to $2.63 - scanx.trade

04:11 AM
pulisher
04:10 AM

AstraZeneca reports first-half growth, disappointment in Ultomiris trial - Sharecast.com

04:10 AM
pulisher
04:10 AM

AstraZeneca quarterly earnings top hopes amid mixed pipeline updates - marketscreener.com

04:10 AM
pulisher
04:09 AM

Why is AstraZeneca stock climbing today? By Investing.com - Investing.com Nigeria

04:09 AM
pulisher
04:08 AM

AstraZeneca shares climbs as full-year outlook reiterated despite recent trial failureUPDATE - Proactive financial news

04:08 AM
pulisher
03:56 AM

AstraZeneca Q2 profit beats estimates as cancer drug sales drive growth (AZN:NYSE) - Seeking Alpha

03:56 AM
pulisher
03:39 AM

AstraZeneca Beats Second-Quarter Earnings Forecast - Share Talk

03:39 AM
pulisher
03:38 AM

ASTRAZENECA : Receives a Buy rating from JP Morgan - marketscreener.com

03:38 AM
pulisher
03:20 AM

AstraZeneca PLC Declares First Interim Dividend for 2026, Payable on September 8, 2026 - marketscreener.com

03:20 AM
pulisher
03:20 AM

AstraZeneca PLC Reconfirms Earnings Guidance for the Year 2026 - marketscreener.com

03:20 AM
pulisher
03:20 AM

AstraZeneca PLC reports results for the quarter ended June 30Earnings Summary - TradingView

03:20 AM
pulisher
03:05 AM

AstraZeneca PLC Reports Statistically Significant Improvement in Overall Survival with Sonesitatug Vedotin in CLDN18.2-Positive Advanced Gastric Cancers - marketscreener.com

03:05 AM
pulisher
03:00 AM

AstraZeneca's rare disease drug misses main goal in late-stage trial - marketscreener.com

03:00 AM
pulisher
02:56 AM

AstraZeneca’s Ultomiris misses primary endpoint in adult HSCT-TMA trial - Investing.com

02:56 AM
pulisher
02:56 AM

AstraZeneca Posts Sales Growth on Oncology Strength - marketscreener.com

02:56 AM
pulisher
02:47 AM

AstraZeneca’s Sone-Ve shows survival benefit in gastric cancer By Investing.com - Investing.com Nigeria

02:47 AM

Astrazeneca Plc Stock (AZN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
NVS NVS
$156.11
price up icon 0.71%
NVO NVO
$49.67
price up icon 1.85%
MRK MRK
$130.76
price down icon 0.24%
$376.26
price up icon 0.06%
$130.52
price up icon 0.94%
Cap:     |  Volume (24h):